Acelyrin Past Earnings Performance
Past criteria checks 0/6
Acelyrin's earnings have been declining at an average annual rate of -6.7%, while the Biotechs industry saw earnings growing at 15.9% annually.
Key information
-6.7%
Earnings growth rate
92.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -37.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Acelyrin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -240 | 78 | 251 |
| 31 Dec 23 | 0 | -382 | 63 | 225 |
| 30 Sep 23 | 0 | -306 | 47 | 154 |
| 30 Jun 23 | 0 | -237 | 30 | 92 |
| 31 Mar 23 | 0 | -225 | 20 | 75 |
| 31 Dec 22 | 0 | -65 | 14 | 56 |
Quality Earnings: SLRN is currently unprofitable.
Growing Profit Margin: SLRN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SLRN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SLRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: SLRN has a negative Return on Equity (-37.29%), as it is currently unprofitable.